Future of Drug Discovery21 Maalis 2023

Antiverse: Engineering the Future of Drug Discovery - Murat Tunaboylu - #8

Are you curious about the latest advancements in AI-enabled antibody discovery? In this podcast series, we dive into the world of Antiverse - we are accelerating drug discovery against difficult targets, including GPCRs and ion channels, using machine learning and phage display techniques.

Join us as we discuss our mission to target cancer, cardiovascular disease, and other challenging conditions. Discover how we leverage AI and wet lab innovation to accelerate the discovery and development of biologics. Plus, learn about our unique approach to antibody discovery, our progress with our internal pipeline of antibodies against GPCRs and other challenging targets, as well as our exciting ongoing collaborations. Tune in and join us at the forefront of antibody discovery!

Things mentioned:

⁠Murat Tunaboylu, Co-Founder and CEO of Antiverse.
Twist Bioscience, a Synthetic Biology company that develops and manufactures synthetic DNA.
⁠Antiverse, an AI-first biologics discovery company that designs antibodies against difficult -to-drug targets.

Watch the full presentation, with slides! https://youtu.be/cRHxi4MWExQ

Additional Materials:

⁠Contact us about your discovery projects by emailing partnerships@antiverse.io.

About Antiverse:

Antiverse was co-founded in 2017 with the goal of engineering the future of drug discovery to change people's lives. Based in Cardiff, Antiverse combines machine learning and phage display techniques to model antibody-antigen interactions. The current version of the platform uses next-generation sequencing and AI to design diverse antibody candidates for any given target. The technology is being developed to enable the discovery of biologics for difficult-to-drug targets associated with cancer, heart, and lung diseases.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(18)

AI Statistical Programming for FDA Submissions - Louise Liu - #18

In this episode of Future of Drug Discovery, we speak with Louise Liu, Founder and CEO of Hill Research. The statistical programming behind an FDA submission is one of the slower steps in clinical dev...

20 Touko 25min

Rahmad Akbar - Frontiers of AI Antibody Design (FODD #17)

This episode is a discussion between ⁠Rahmad Akbar, Senior Data Scientist in Antibody Design at Novo Nordisk and Murat Tunaboylu⁠, Co-Founder and CEO of Antiverse⁠. You will learn: The impact anti...

3 Syys 202426min

Paul Essery and Murat Tunaboylu - Founding an AI Drug Discovery Start-Up (FODD #16)

This episode is a discussion between Paul Essery, Host of 'The Tech Business Podcast' and Murat Tunaboylu Co-Founder and CEO of Antiverse. You will learn: The CEO journey and how Antiverse was fou...

23 Heinä 202414min

Inorganic Chemistry at the Frontier of Immunotherapy - Björn Schimmöller - #15

In this episode, we speak with ⁠⁠Björn Schimmöller, Co-Founder and CEO of iuvantium, a synthetic immunobiology company developing new modalities for the next generation of immunotherapies.Host: ⁠⁠Mura...

17 Tammi 202422min

AI, Automation and Drug Discovery - Ashwini Ghogare - #14

In this episode, we speak with ⁠Ashwini Ghogare⁠, Head of Artificial Intelligence and Automation in Drug Discovery at ⁠MilliporeSigma⁠, the Global Science and Technology Group at ⁠Merck⁠.Host: ⁠Murat ...

11 Joulu 202326min

Unleashing the Power of Computational Biology - Ming 'Tommy' Tang - #13

In this talk, Murat speaks with Ming (Tommy) Tang, Director of Computational Biology at Immunitas Therapeutics, an immuno-oncology start-up developing novel therapeutics for patients with cancer. Tomm...

20 Loka 202333min

Digital Foundations For Rapid Healthcare Advancement - Nikhil Reddy Podduturi - #12

In this talk, Murat speaks with ⁠Nikhil Podduturi⁠, Head of Data Science at the Digital Lab of ⁠Boehringer Ingelheim⁠ - ⁠(BI X)⁠. Nikhil co-leads the laboratory and data science chapters at the BI X ...

6 Loka 202327min

Machine Learning Blueprints for Pharma Discovery Breakthroughs - Abhishek Pandey - #11

In this talk, Murat speaks with Abhishek Pandey, Principle Research Scientist and Pharma Discovery Group Lead at AbbVie. Abhishek currently leads RAIDERS, a Pharma Discovery group integrating machine ...

2 Touko 202327min